A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...

Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced that new real-world evidence evaluating ...

Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...